https://oligomerix.com/latest-news/ 2026-06-11T17:28:20+00:00 https://oligomerix.com/latest-news/nanodetection-technology-and-oligomerix-announce-exclusive-global-licensing-agreement-for-breakthrough-neurodegenerative-diagnostic-antibodies/ 2026-06-11T16:41:36+00:00 https://oligomerix.com/latest-news/oligomerix-completes-ph-1a-clinical-study-on-olx-07010/ 2026-06-11T16:42:24+00:00 https://oligomerix.com/latest-news/oligomerix-awarded-0-5-m-phase-i-nih-sbir-fast-track-grant-to-conduct-safety-studies-that-will-support-clinical-studies-of-olx-07010-for-alzheimers-patients/ 2026-06-11T16:42:59+00:00 https://oligomerix.com/latest-news/oligomerix-elects-new-chairman-william-caple-to-board-of-directors/ 2026-06-11T16:43:29+00:00 https://oligomerix.com/latest-news/oligomerix-publishes-preclinical-data-on-novel-small-molecule-therapeutic-in-development-for-alzheimers-disease-and-rare-neurodegenerative-diseases/ 2026-06-11T16:44:06+00:00 https://oligomerix.com/latest-news/oligomerix-announces-first-in-human-dosing-of-tau-self-association-inhibitor-olx-07010/ 2026-06-11T16:44:39+00:00 https://oligomerix.com/latest-news/oligomerix-announces-issuance-of-key-u-s-patent-for-lead-tau-targeting-candidate-olx-07010-to-treat-neurodegenerative-diseases/ 2026-06-11T16:45:19+00:00 https://oligomerix.com/latest-news/oligomerix-presents-data-from-ind-enabling-studies-on-clinical-candidate-at-clinical-trials-on-alzheimers-disease-ctad-and-neuroscience-2022-meetings/ 2026-06-11T16:46:02+00:00 https://oligomerix.com/latest-news/taking-a-new-approach-to-tackle-neurodegenerative-diseases/ 2026-06-11T16:46:25+00:00 https://oligomerix.com/latest-news/oligomerix-awarded-2-49m-from-nih-to-further-support-clinical-development-of-tau-targeting-alzheimers-disease-therapy-candidate-olx-07010/ 2026-06-11T16:47:02+00:00 https://oligomerix.com/latest-news/oligomerix-awarded-3-35m-from-nih-to-support-clinical-development-of-tau-targeting-alzheimers-disease-therapy/ 2026-06-11T16:47:38+00:00 https://oligomerix.com/latest-news/oligomerix-announces-key-organizational-changes-in-transition-to-clinically-focused-company/ 2026-06-11T16:48:14+00:00 https://oligomerix.com/latest-news/oligomerix-presents-data-on-lead-program-at-clinical-trials-on-alzheimers-disease-ctad-conference-and-society-for-neuroscience-meeting/ 2026-06-11T16:49:33+00:00 https://oligomerix.com/latest-news/oligomerix-presents-preclinical-data-showing-efficacy-of-differentiated-approach-targeting-tau-in-models-of-alzheimers-disease-and-related-tauopathies/ 2026-06-11T16:50:05+00:00 https://oligomerix.com/latest-news/oligomerix-to-present-at-alzheimers-association-international-conference/ 2026-06-11T16:50:40+00:00 https://oligomerix.com/latest-news/oligomerix-appoints-chief-medical-officer-william-erhardt-m-d-to-board-of-directors/ 2026-06-11T16:51:17+00:00 https://oligomerix.com/latest-news/oligomerix-to-participate-in-upcoming-life-sciences-conferences/ 2026-06-11T16:51:51+00:00 https://oligomerix.com/latest-news/westchester-county-association-all-access-healthcare-spotlight-on-westchesters-bioscience-ecosystem-oligomerix/ 2026-06-11T16:52:26+00:00 https://oligomerix.com/latest-news/oligomerix-to-present-at-upcoming-life-sciences-conferences/ 2026-06-11T16:52:58+00:00 https://oligomerix.com/latest-news/fighting-neurodegeneration-with-tau-tangle-blocking-oligomerix-ceo-james-moe-explains/ 2026-06-11T16:53:34+00:00 https://oligomerix.com/latest-news/oligomerix-to-present-at-clinical-trials-on-alzheimers-disease-conference-life-sciences-summit/ 2026-06-11T16:54:08+00:00 https://oligomerix.com/latest-news/alzheimers-biotech-firm-moves-hq-to-white-plains-crains-new-york-business-health-pulse/ 2026-06-11T16:54:39+00:00 https://oligomerix.com/latest-news/oligomerix-relocation-of-headquarters-bioworld/ 2026-06-11T16:55:10+00:00 https://oligomerix.com/latest-news/oligomerix-relocates-headquarters-to-accommodate-growth/ 2026-06-11T16:55:39+00:00 https://oligomerix.com/latest-news/oligomerix-awarded-a-3-19-million-grant-from-nia-bioworld/ 2026-06-11T16:56:16+00:00 https://oligomerix.com/latest-news/oligomerix-receives-3-19-million-nih-commercialization-readiness-pilot-grant-for-alzheimers-disease-therapy/ 2026-06-11T16:56:52+00:00 https://oligomerix.com/latest-news/oligomerix-to-present-at-aaic-2020-conference-on-small-molecule-inhibitor-of-tau-self-association/ 2026-06-11T16:57:23+00:00 https://oligomerix.com/latest-news/oligomerix-appoints-william-erhardt-m-d-as-chief-medical-officer/ 2026-06-11T16:58:22+00:00 https://oligomerix.com/latest-news/oligomerix-announces-appointment-of-robert-foerster-former-pfizer-executive-as-chief-financial-officer/ 2026-06-11T16:58:56+00:00 https://oligomerix.com/latest-news/oligomerix-presents-preclinical-data-at-tau2020-global-conference-for-small-molecule-inhibitor-of-tau-self-association/ 2026-06-11T16:59:31+00:00 https://oligomerix.com/latest-news/oligomerix-to-present-at-bio-ceo-investor-conference-tau2020-global-conference/ 2026-06-11T17:00:01+00:00 https://oligomerix.com/latest-news/study-might-point-alzheimers-research-in-whole-new-direction-u-s-news/ 2026-06-11T17:00:42+00:00 https://oligomerix.com/latest-news/newly-discovered-drug-is-able-to-inhibit-neurotoxic-tau-oligomers-in-brains-paving-the-way-for-a-potential-cure-for-alzheimer/ 2026-06-11T17:01:14+00:00 https://oligomerix.com/latest-news/oligomerix-and-feinstein-institutes-publish-in-vivo-alzheimers-disease-treatment-data/ 2026-06-11T17:01:49+00:00 https://oligomerix.com/latest-news/oligomerix-awarded-2-18-million-sbir-grant-for-tau-oligomer-inhibitor-for-alzheimers-disease-and-related-disorders/ 2026-06-11T17:02:20+00:00 https://oligomerix.com/latest-news/oligomerix-receives-ongoing-support-from-nih-and-moves-forward-with-ind-enabling-studies/ 2026-06-11T17:02:51+00:00 https://oligomerix.com/latest-news/oligomerix-to-participate-in-the-nih-innovation-zone-at-2019-bio-international-convention/ 2026-06-11T17:03:21+00:00 https://oligomerix.com/latest-news/oligomerix-awarded-1-98-million-nih-sbir-phase-iib-grant/ 2026-06-11T17:04:07+00:00 https://oligomerix.com/latest-news/oligomerix-relocates-to-albert-einstein-college-of-medicine-campus/ 2026-06-11T17:04:38+00:00 https://oligomerix.com/latest-news/oligomerix-inc-awarded-2-49-million-fast-track/ 2026-06-11T17:05:27+00:00 https://oligomerix.com/latest-news/oligomerix-inc-awarded-national-institute-on-aging-sbir-grant-for-development-of-alzheimers-disease-specific-biomarker/ 2026-06-11T17:05:51+00:00 https://oligomerix.com/latest-news/oligomerix-awarded-a-grant-for-its-alzheimers-drug-discovery-program-targeting-tau-oligomers-from-the-national-institutes-of-health/ 2026-06-11T17:06:19+00:00 https://oligomerix.com/latest-news/oligomerix-to-present-at-biotech-showcasetm-2014/ 2026-06-11T17:06:47+00:00 https://oligomerix.com/latest-news/taconic-and-oligomerix-to-collaborate-on-tau-mouse-model-characterization-for-use-in-alzheimers-disease-research/ 2026-06-11T17:07:14+00:00 https://oligomerix.com/latest-news/identification-of-a-tau-oligomer-structure-that-is-toxic-to-neurons/ 2026-06-11T17:07:43+00:00 https://oligomerix.com/latest-news/oligomerix-awarded-phase-iib-grant-from-the-nih-to-discover-drugs-that-inhibit-alzheimers-disease-progression/ 2026-06-11T17:08:16+00:00 https://oligomerix.com/latest-news/oligomerix-inc-to-present-multiple-posters-highlighting-its-tau-focused-technology-during-the-annual-alzheimers-association-international-conference/ 2026-06-11T17:08:43+00:00 https://oligomerix.com/latest-news/oligomerix-inc-completes-series-b-financing/ 2026-06-11T17:09:10+00:00 https://oligomerix.com/latest-news/oligomerix-inc-completes-2-million-series-a-financing/ 2026-06-11T17:09:39+00:00 https://oligomerix.com/latest-news/sfn-2010-press-release-validation-of-extracellular-tau-oligomer-target/ 2026-06-11T17:10:07+00:00 https://oligomerix.com/latest-news/oligomerix-awarded-phase-ii-nih-grant-to-discover-novel-drugs-for-alzheimers-disease/ 2026-06-11T17:10:33+00:00 https://oligomerix.com/latest-news/oligomerix-announces-board-changes-vic-micati-appointed-chairman-and-jack-pasini-appointed-company-director-and-chief-commercial-officer/ 2026-06-11T17:11:04+00:00 https://oligomerix.com/latest-news/oligomerix-awarded-nih-grant-to-develop-novel-biomarkers-for-alzheimers-disease/ 2026-06-11T17:11:31+00:00 https://oligomerix.com/latest-news/oligomerix-funded-by-the-alzheimers-drug-discovery-foundation-to-evaluate-compounds-active-against-tau-oligomers-a-novel-target-for-therapeutic-development/ 2026-06-11T17:11:58+00:00 https://oligomerix.com/latest-news/victor-p-micati-joins-oligomerixs-board-of-directors/ 2026-06-11T17:12:29+00:00 https://oligomerix.com/latest-news/oligomerix-awarded-nih-grant-to-develop-novel-drug-discovery-technology-for-alzheimers-disease/ 2026-06-11T17:12:56+00:00 https://oligomerix.com/latest-news/oligomerix-announces-series-b-extension-raise-of-2-7-million-to-support-phase-1-clinical-development/ 2026-06-11T17:28:20+00:00